News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020

August 4, 2020

Affimed Announces Annual General Meeting of Shareholders

July 10, 2020

Affimed Reports First Quarter 2020 Financial Results and Operational Progress

June 23, 2020

Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed’s ROCK^® Platform, at AACR Virtual Annual Meeting II

June 22, 2020

Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

June 17, 2020

Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference

June 16, 2020

Affimed Announces Appointment of Angus Smith as Chief Financial Officer

June 11, 2020

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

May 29, 2020

Affimed to Present at the Jefferies Virtual Healthcare Conference

May 28, 2020

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK^® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

May 15, 2020

Events

All

Scientific

Investors

26Sep

NK2023

September 26 - 29, 2023 (Oslo, Norway)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed to Report Second Quarter 2020 Financial Results & Corporate Update August 11, 2020

Affimed Announces Annual General Meeting of Shareholders

Affimed Reports First Quarter 2020 Financial Results and Operational Progress

Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed’s ROCK^® Platform, at AACR Virtual Annual Meeting II

Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference

Affimed Announces Appointment of Angus Smith as Chief Financial Officer

Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting

Affimed to Present at the Jefferies Virtual Healthcare Conference

Affimed Announces Abstracts on Innate Cell Engagers from its ROCK^® Platform Accepted for Presentation at AACR Virtual Annual Meeting II

Events

NK2023